Luanne Marie Metz
Luanne Marie Metz
University of Calgary
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
CH Polman, SC Reingold, G Edan, M Filippi, HP Hartung, L Kappos, ...
Annals of neurology 58 (6), 840-846, 2005
A full genome search in multiple sclerosis
GC Ebers, K Kukay, DE Bulman, AD Sadovnick, G Rice, C Anderson, ...
Nature genetics 13 (4), 472-476, 1996
Major depression in multiple sclerosis A population-based perspective
SB Patten, CA Beck, JVA Williams, C Barbui, LM Metz
Neurology 61 (11), 1524-1527, 2003
A population‐based study of multiple sclerosis in twins: update
AD Sadovnick, H Armstrong, GPA Rice, D Bulman, L Hashimoto, ...
Annals of neurology 33 (3), 281-285, 1993
The promise of minocycline in neurology
VW Yong, R Zabad, T Todoruk, LM Metz
Journal of Neurochemistry 94, 71, 2005
The promise of minocycline in neurology
VW Yong, J Wells, F Giuliani, S Casha, C Power, LM Metz
The Lancet Neurology 3 (12), 744-751, 2004
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis
V Brundula, NB Rewcastle, LM Metz, CC Bernard, VW Yong
Brain 125 (6), 1297-1308, 2002
endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms
JA Rogers, L Metz, VW Yong
Molecular immunology 53 (4), 421-430, 2013
Long-term medical conditions and major depression: strength of association for specific conditions in the general population
SB Patten, CA Beck, A Kassam, JVA Williams, C Barbui, LM Metz
The Canadian Journal of Psychiatry 50 (4), 195-202, 2005
Burden of illness of multiple sclerosis: Part I: Cost of illness
A Auty, C Belanger, JP Bouchard, DG Brunet, P Duquette, GS Francis, ...
Canadian Journal of Neurological Sciences 25 (1), 23-30, 1998
Regional variation of multiple sclerosis prevalence in Canada
CA Beck, LM Metz, LW Svenson, SB Patten
Multiple Sclerosis Journal 11 (5), 516-519, 2005
Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population
SB Patten, LM Metz, MA Reimer
Multiple Sclerosis Journal 6 (2), 115-120, 2000
A comparison of health utility measures for the evaluation of multiple sclerosis treatments
JD Fisk, MG Brown, IS Sketris, LM Metz, TJ Murray, KJ Stadnyk
Journal of Neurology, Neurosurgery & Psychiatry 76 (1), 58-63, 2005
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis
LM Metz, Y Zhang, M Yeung, DG Patry, RB Bell, CA Stoian, VW Yong, ...
Annals of neurology 55 (5), 756-756, 2004
Randomized multicenter trial of natalizumab in acute MS relapses Clinical and MRI effects
PW O’connor, A Goodman, AJ Willmer-Hulme, MA Libonati, L Metz, ...
Neurology 62 (11), 2038-2043, 2004
Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators
VW Yong, RK Zabad, S Agrawal, AG DaSilva, LM Metz
Journal of the neurological sciences 259 (1), 79-84, 2007
Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)
J Bakker, L Metz
Canadian Journal of Neurological Sciences 31 (2), 265-267, 2004
Major depression and quality of life in individuals with multiple sclerosis
J Li Wang, MA Reimer, LM Metz, SB Patten
The International Journal of Psychiatry in Medicine 30 (4), 309-317, 2000
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
RK Zabad, LM Metz, TR Todoruk, Y Zhang, JR Mitchell, M Yeung, ...
Multiple Sclerosis Journal 13 (4), 517-526, 2007
Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis
LM Metz, DKB Li, AL Traboulsee, P Duquette, M Eliasziw, G Cerchiaro, ...
New England Journal of Medicine 376 (22), 2122-2133, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20